Selecta Biosciences Inc Stock News

-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- -U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions-

Cubist Systematic Strategies LLC increased its position in shares of Selecta Biosciences, Inc. (NASDAQ:SELB) by 29.1% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 95,446 shares of the companys stock after purchasing an additional 21,508 shares during the quarter. Cubist Systematic Strategies LLCs holdings in Selecta Biosciences were worth $399,000 at the []

Analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB) to announce sales of $20.58 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Selecta Biosciences earnings. The highest sales estimate is $21.15 million and the lowest is $20.00 million. Selecta Biosciences reported sales of $11.95 million during the same quarter last []

Man Group plc lessened its holdings in Selecta Biosciences, Inc. (NASDAQ:SELB) by 26.7% during the second quarter, Holdings Channel reports. The fund owned 155,437 shares of the companys stock after selling 56,710 shares during the period. Man Group plcs holdings in Selecta Biosciences were worth $650,000 as of its most recent filing with the Securities []

Goldman Sachs Group Inc. cut its holdings in Selecta Biosciences, Inc. (NASDAQ:SELB) by 24.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,614,327 shares of the companys stock after selling 511,812 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.43% []

Selecta Biosciences (NASDAQ:SELB)s stock had its buy rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Monday, TipRanks reports. They currently have a $6.00 target price on the stock. HC Wainwrights price objective would suggest a potential upside of 69.49% from the stocks previous close. Other analysts []

Zacks Investment Research downgraded shares of Selecta Biosciences (NASDAQ:SELB) from a hold rating to a sell rating in a research note published on Saturday morning, Zacks.com reports. According to Zacks, Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a []

Equities analysts forecast that Selecta Biosciences, Inc. (NASDAQ:SELB) will post ($0.07) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Selecta Biosciences earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.06). Selecta Biosciences reported earnings of ($0.14) per share in the same quarter []

Selecta Biosciences, Inc.'s (SELB) CEO Carsten Brunn on Q3 2021 Results - Earnings Call Transcript

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for t

Selecta Biosciences Inc (NASDAQ: SELB) announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of neutralizing antibodies against an adeno-associa

Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.  Th

WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ther

Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | Pen